Integrating in-silico and experimental validation approaches to unveil the therapeutic mechanism of naringenin against breast cancer.

A relapse-free survival (RFS) analysis conducted on 4,929 BC patients over a follow-up period of approximately 300 months revealed that higher SRC expression correlated with poorer RFS, with an HR of 0.63 and a highly significant p-value of 4.1e-09 (Fig. 7 b).

also in 132,142 other papers